[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"frail\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:frail":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,45,80,111,139,165,204,225,265],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100606424","resilience-enhancement-using-electronic-frailty-index-directed-care-pathway-100606424",false,"NCT07175376","Resilience Enhancement Using Electronic Frailty Index-Directed Care Pathway","Resilience Enhancement Utilizing an Electronic Frailty Index-Directed Care Pathway for Older Adults Receiving Chemotherapy (RESILIENCE-e): A Prospective Single-Arm Interventional Study","Inclusion Criteria:\n\nPatients with cancer:\n\n* Ability to understand and willingness to sign an IRB-approved informed consent\n* Age ≥ 65 years at the time of enrollment.\n* Planned to initiate an outpatient chemotherapy regimen (including myelosuppressive biologic\u002Fimmune therapies) for cancer treatment (any type or stage), either as an initial therapy or as a new line of therapy, with curative or palliative intent.\n* eFI pre-frail or frail status (available in EHR; defined as eFI \\> 0.10) within 30 days before enrollment.\n* Ability to read and understand the English language\n\nProviders:\n\n* Treating medical oncologist of at least one patient participant who enrolled on to the study and completed baseline assessment.\n\nExclusion Criteria:\n\nPatients:\n\n* Documented physical or psychological comorbidity that would limit participant's ability to understand or comply with study procedures for the entire length of the study per the enrolling investigator.\n* Chemotherapy planned at a facility outside the Atrium Health system.\n* Currently receiving chemotherapy (defined as planned to continue an on-going treatment rather than starting a new regimen).","ALL","65 Years",{"count":19,"type":20},32,"ESTIMATED","INTERVENTIONAL",[23],"NA","The study purpose is to gain a better understanding of the needs of adults aged 65 and older while they are receiving chemotherapy by measuring their resilience and tailor care plans based on their individual needs.",[26,27,28],"Cancer","Frail","Chemotherapy",[26,30,31],"Frailty Index","eFI score","RECRUITING","2026-07-01",{"date":35,"type":36},"2026-07-02","ACTUAL",{"date":38,"type":36},"2026-03-16",{"date":40,"type":20},"2027-05",{"name":42,"class":43},"Wake Forest University Health Sciences","OTHER",2,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":79},"100235143","genetic-and-epigenetic-signatures-of-translational-aging-laboratory-testing-gestalt-100235143","NCT02339012","Genetic and Epigenetic Signatures of Translational Aging Laboratory Testing (GESTALT)","The Genetic and Epigenetic Signatures of Translational Aging Laboratory Testing (GESTALT)","* Since the study of gene expression and epigenetic regulation are essential aims of GESTALT, all participants are required to consent to DNA\u002FRNA testing and storage at all visits. Participants that refuse genetic testing and storage will not be eligible to participate or to continue to participate in the study.\n\nThe criteria below for each group pertains only to the Screening and Baseline Visits, except where otherwise noted. If any of the conditions develop while the participant is in the study, the participant remains in the study. However, participants that develop severe cognitive problems and are diagnosed by the cognition group with dementia, will no longer be able to participate in the study.\n\nINCLUSION CRITERIA for the Healthy Group:\n\n* Age greater than or equal to 20 years of age.\n* Are willing to return every 2 years for study visit procedures.\n* Agree to genetic (DNA\u002FRNA) sample collection, analysis and storage.\n* Have good venous access for cytapheresis and are in good health as determined by the Apheresis Health History Questionnaire and are found eligible for apheresis (Apheresis Eligibility form).\n* Weigh greater than or equal to 110lbs and a body mass index (BMI) \\\u003C 30.\n* Do not have established genetic diseases such as sickle cell, hemochromatosis (iron overload), cystic fibrosis or Ehlers-Danlos syndrome (connective tissue disorder).\n* Do not have autoimmune diseases such as Hashimoto's thyroiditis, Myasthenia Gravis or Rheumatoid arthritis.\n* Report that they are able to perform daily self- care without assistance.\n* Report that they able to walk independently for at least 400 meters without assistance and without developing severe symptoms.\n* Report they are able to perform normal activities of daily living without shortness of breath (walking or climbing stairs) or other severe symptoms.\n* Do not have cognitive impairment based on mental status screening tests and evaluations and in the absence of any drug treatment.\n* Do not have a history of cardiovascular disease or cerebrovascular disease including angina (requiring treatment), myocardial infarction, congestive heart failure, uncontrolled hypertension, pacemaker, stroke, or transient ischemic attacks (TIA).\n* Do not have a history of diabetes (requiring any medical treatment other than diet and exercise) and their fasting Glucose is \\\u003C126 mg\u002FdL.\n* Do not have active (any activity in the last 10 years) cancer, except for locally limited squamous and basal cell cancer.\n* Do not have clinically significant hormonal dysfunction (Self-reported or laboratory values out of range. Mild hypothyroidism in participants over 60 is not considered exclusion).\n* Do not have a history of neurological diseases or birth defects (other than minor anatomical abnormalities, which do not affect physical and\u002For cognitive function).\n* Do not have a history of kidney or liver disease (associated with reduced kidney or liver function).\n* Do not have a history of severe gastrointestinal (G.I.) diseases, with symptoms or requiring chronic treatment such as gastroesophageal reflux disease (GERD), Crohn s disease or ulcerative colitis.\n* Do not have a history of severe pulmonary disease such as chronic obstructive pulmonary disease (COPD) or asthma requiring continuous medication use.\n* Do not have muscle-skeletal conditions due to diseases or traumas (that cause pathological weakness and\u002For chronic pain).\n* Do not have a history of severe psychiatric conditions associated with behavioral problems or requiring absolute and continuous need for medical treatment.\n* Do not have any medical condition that requires absolute and continuous need for long term treatment with antibiotics, corticosteroids, immunosuppressors, H2 blockers and\u002For proton pump inhibitors, or pain medications.\n* Do not have a medical condition that requires the use of chronic anticoagulant medication such as Coumadin, heparin, or antiplatelet agents other than low dose aspirin.\n* Do not have important sensory deficits (legally blind and\u002For any condition that precludes the participant from being tested with standard neuropsychological tests or providing informed consent).\n* Are able to read and speak English.\n* Are able to understand the study risks and procedures, and consent to participate in the study.\n* Not currently pregnant or a nursing mother.\n* Do not currently smoke and have not smoked in the past 3 months.\n* Veins are adequate for cytapheresis.\n* No current illness that as judged by the study physician substantially increases the risks associated with cytapheresis (active infections, allergies, etc.).\n* No history of allergy to acid- citrate- dextrose (ACD) anticoagulant.\n* No history of an active bleeding disorder such as hemophilia or Von Willebrand disease.\n* No history of seizures within the last 3 months.\n* No history of Lyme disease, unless six weeks' post treatment and no new symptoms, of Chagas disease, Babesiosis, or Leishmanias.\n* Are not claustrophobic and are eligible to perform 3TMRI as per the MRI eligibility form.\n* Do not have hip or knee replacements or other medical conditions that prevent 3TMRI research scans from being performed.\n\nINCLUSION CRITERIA for the Non-Healthy-or-Frail and Frail groups:\n\n* Age \\>= 20 years of age in the NHF group.\n* Age \\>= 50 years of age in the F group.\n* Are willing to return every 2 years for study visit procedures.\n* Agree to genetic (DNA\u002FRNA) sample collection, analysis, and storage.\n* Have good venous access for blood sampling.\n* Weigh \\>= 110lbs and a body mass index (BMI) \\\u003C= 35.\n* Do not have established genetic diseases such as sickle cell, hemochromatosis (iron overload), cystic fibrosis or Ehlers-Danlos syndrome (connective tissue disorder).\n* Do not have important sensory deficits (legally blind and\u002For any condition that precludes the participant from being tested with standard neuropsychological tests or providing informed consent).\n* Are able to read and speak English.\n* Are able to understand the study risks and procedures, and consent to participate in the study.\n* Not currently pregnant or a nursing mother.\n* No current acute medical condition.\n* No history of an active bleeding disorder such as hemophilia or Von Willebrand disease.\n* No history of seizures within the last 3 months.\n* Are not claustrophobic and are eligible to perform 3TMRI as per the MRI eligibility form.\n* Do not have other medical conditions that prevent 3TMRI research scans from being performed.\n* Frail participants meet the A and B criteria as reported.\n* Not-Healthy-or-Frail participants will not be eligible for the Healthy group because of medical or functional problems and also do not meet the criteria for the Frail Group.\n\nParticipant Exclusion Criteria:\n\nThese criteria pertain to the Screening and Baseline Visits. If conditions considered as exclusion criteria for study entry develop any time after the Baseline evaluation, the participant remains in the study.\n\nExclusion Criteria:\n\n* HIV virus infection (all groups).\n* Hepatitis B or C (all groups).\n* Active syphilis, gonorrhea or TB requiring treatment (all groups).\n* WBC \\\u003C3,000 or \\> 12,000\u002Fk\u002FmicroL (only Healthy group).\n* Platelets \\\u003C 100,000 or \\>600,000 k\u002F microL (only Healthy group).\n* Hemoglobin \\\u003C 11.0 gm\u002FdL in women and \\\u003C 12.0 gm\u002FdL in men (only Healthy group).\n* GFR \\\u003C50 mL\u002Fmin\u002F1.73 m\\^2 (only Healthy group)\n* GFR \\\u003C= to 30 (only non-Healthy-or-Frail group or Frail group)\n* Bilirubin \\> 1.5 mg\u002Fdl (unless higher levels can be ascribed to Gilbert's disease (only Healthy group).\n* ALT, AST, or alkaline phosphatase twice the normal serum concentration (only Healthy group).\n* Corrected calcium \\\u003C 8.5 or \\> 10.7 mg\u002Fdl (all groups).\n* Albumin \\\u003C 3.1 g\u002Fdl (only Healthy group).\n* Cholesterol, LDL and\u002For Triglycerides \\>1.5x normal (only Healthy group).\n* Positive Urine Drug Screen (unless taking prescribed medication and at the discretion of the PI) (all groups).\n* Currently pregnant or a nursing mother (all groups).\n\nFurthermore, if the participant is found eligible at Screening and Baseline but fails a urine drug screen (unless taking a prescribed medication and at the discretion of the PI) at any of the subsequent visits, the participant will be asked to return to repeat the test and if positive, will no longer be eligible to participate in the study.",true,"20 Years","120 Years",{"count":56,"type":20},900,"OBSERVATIONAL","Background:\n\n\\- Biomarkers are substances in people s blood and tissues. They help researchers understand diseases and signs of aging. Scientists want to do more research on biomarkers to find ways to improve quality of life in old age.\n\nObjective:\n\n\\- To learn more about biomarkers and their relationship to aging.\n\nEligibility:\n\n\\- Adults at least 20 years old who weigh at least 110 pounds and have a body mass index below 30. They must agree that their genetic samples can be collected, studied, and stored.\n\nDesign:\n\n* Participants will be screened with medical history, physical exam, EKG and blood and urine tests.\n* Participants will have 3-day visits. They will return every 2 years.\n* All visits include:\n* Blood and urine collection\n* Physical performance tests\n* Health questionnaires\n* Memory and problem-solving tests\n* Magnetic Resonance Imaging (MRI) and Computerized Tomography (CT) scans.\n* Muscle metabolism\u002F exercise tests\n* Taste strips\n* Muscle and\u002For skin biopsies\u002F red light therapy\n* Retinal imaging\u002F eye tracking\n* Sleep study\n* ODD visits also include:\n* Cytapheresis\n* Bone marrow aspirate\n* EVEN visits also include:\n* Hyperglycemic CLAMP\n* Lumbar Puncture (LP)\n* Continuous Glucose Monitor (CGM)",[60,61,27],"Healthy Volunteers","Non-Healthy\u002FNon-Frail",[63,64,65,66,67,68],"Genome Wide Association","Biomarkers","Methylation","Phenotype","Cytometry","Natural History","2026-06-23",{"date":71,"type":36},"2026-06-24",{"date":73,"type":36},"2015-03-15",{"date":75,"type":20},"2099-12-31",{"name":77,"class":78},"National Institute on Aging (NIA)","NIH",1,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":88,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":21,"phases":91,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":110},"100630828","effect-of-using-a-reminder-to-encourage-patients-to-be-active-during-their-hospital-stay-100630828","NCT07492745","Effect of Using a Reminder to Encourage Patients to be Active During Their Hospital Stay.","Effect of Using a Reminder to Encourage Patients to be Active During Their Hospital Stay : a Multicenter Randomised Controlled Double Blind Study.","REMOTIVE","Inclusion Criteria:\n\n* Patients aged 50 or over with a score of 4 or above on the Clinical Frailty Scale (vulnerable but not dependent patients, symptoms limiting activities, patients who are slower\u002Fmore fatigued).\n* Must be able to get up from a chair without assistance.\n* Patients must be able to communicate with staff, understand instructions, give consent, and cooperate with staff.\n\nExclusion Criteria:\n\n* Patients with an estimated hospital stay of less than 5 days.\n* Contraindications to physical activity determined by the medical team (e.g., cardiovascular instability, orthopedic contraindications, etc.).\n* Terminal illness.\n* Patients scheduled for surgery.\n* Pregnant women.\n* People who do not understand French.\n* People protected under the law.","50 Years",{"count":90,"type":20},204,[23],"Around 30% of patients aged 65 and over experience functional decline due to hospitalization. Physical inactivity, often without medical justification, is common during hospital stays.This immobility leads to loss of autonomy, muscle strength, and increases post-discharge risks.\n\nSlow walking for 25-40 minutes daily significantly improves functional capacity. However, it could be difficult to reach this time of walking due to a lack of physiotherapist in hospital.\n\nA vibrating watch may encourage patients to walk or perform strengthening exercises. This simple intervention aims to improve function without requiring additional staff or resources",[94,27],"Inpatients",[96,97,98,99,100],"inpatients","physical activity","reminder device","frailty","functional independancy","2026-06-15",{"date":103,"type":36},"2026-06-16",{"date":105,"type":36},"2025-11-19",{"date":107,"type":20},"2029-01-01",{"name":109,"class":43},"Groupe Hospitalier du Havre",4,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":21,"phases":122,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":135,"leadSponsor":137,"locationsCount":44},"100615424","cognitive-motor-technology-rehabilitation-in-frail-individuals-100615424","NCT07292428","Cognitive-motor Technology Rehabilitation in Frail Individuals","An Integrated and Multi-perspective Approach to Cognitive-motor Technology Rehabilitation and Telemedicine in Frail Individuals","FIT4COG","Inclusion Criteria:\n\n* Age between 65 and 90 years;\n* Presence of chronic sensorimotor and\u002For cognitive disabilities;\n* Cognitive abilities that allow the patient to carry out simple orders and understand the physiotherapist's instructions \\[assessed using the Token Test (score ≥ 26.5)\\];\n* Ability to walk independently or with minimal assistance;\n* Ability to understand and sign the informed consent form.\n\nExclusion Criteria:\n\n* Presence of systemic, neurological, or cardiac conditions that make walking risky or cause motor deficits;\n* Oncological conditions, orthopedic or postural problems, presence of plantar ulcers;\n* Partial or total amputation of segments of the foot.\n* Inability to provide informed consent.","90 Years",{"count":121,"type":20},80,[23],"Dual performance, which involves the simultaneous execution of motor and cognitive tasks, is a fundamental aspect of everyday functioning. In the elderly population, for example, the ability to manage dual tasks can be significantly impaired, resulting in an increased risk of falls and further cognitive decline. The ability to perform two tasks simultaneously (one motor and one cognitive) is often impaired in patients with chronic sensorimotor and\u002For cognitive disabilities, with repercussions on both physical and cognitive abilities. Patients with chronic sensorimotor and\u002For cognitive disabilities consistently show greater deficits in dual performance than healthy individuals, with repercussions on both motor and cognitive functioning. These deficits are influenced by psychological, neural, and disease-specific factors, but targeted interventions and dual-task training can help improve outcomes.\n\nSome authors have pointed out that dual-task training can improve attention, functional mobility, and overall cognitive function more effectively than single-task training. One of the main advantages of dual-task training is the reduction of the risk of falls in the elderly population and in chronic patients with sensorimotor disorders: dual-task training has been shown to improve dynamic balance and stability, even during walking, and cognitive function.\n\nTelerehabilitation is a branch of telemedicine that uses different types of technology to provide remote rehabilitation services. Telerehabilitation, like telemedicine, can be delivered through three distinct mechanisms: synchronous mode, in which the patient and physician communicate in real time using technological tools; remote monitoring mode, in which the patient's condition is monitored remotely; and asynchronous mode, in which there is no simultaneous communication between the parties involved. This approach has proven particularly effective during the recent COVID-19 pandemic, minimizing risks and improving clinical outcomes. In addition, it has proven to be a safe way to monitor clinical parameters, with the possibility of personalized and timely intervention for patients with chronic conditions, leading to improved patient condition and quality of life, while also helping to reduce costs for both the patient and the healthcare system. Asynchronous telemedicine and\u002For telerehabilitation activities, in which the patient and operator are not online at the same time, also enable patients living in remote areas with limited or unreliable connectivity to receive convenient, flexible, and accessible healthcare services.",[27,125],"Sensorimotor Deficits",[127,128,129,130],"Frailty","Sensorimotor impairment","Technology rehabilitation","Dual-task condition","2026-02-02",{"date":133,"type":36},"2026-02-03",{"date":131,"type":36},{"date":136,"type":20},"2026-11-30",{"name":138,"class":43},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":16,"minAge":146,"maxAge":54,"enrollmentInfo":147,"targetDuration":4,"studyType":21,"phases":149,"briefSummary":150,"conditions":151,"keywords":152,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":4},"100606512","ai-assisted-rehabilitation-in-frailty-100606512","NCT07176520","AI-Assisted Rehabilitation In Frailty","AI-Assisted Rehabilitation for Frail Older Adults Discharged From Community Hospitals: A Hybrid Effectiveness-Implementation Trial","Inclusion Criteria:\n\n* Adults aged ≥ 21years\n* Clinical Frailty Score (CFS) 4 to 6 \\*\n* Provided informed consent (for cognitively impaired persons MMSE\\\u003C18, next-of-kin or proxy to give consent).\n* Have access to smartphone\u002Ftablet (own or loaned from investigators)\u002F\n\nExclusion Criteria:\n\n* Medical conditions precluding safe home exercises or severely affect interaction with AI-tool (angina, vision loss, hearing impairment).\n* Cognitive impairment (MMSE\\\u003C18) and no caregiver to assist with use of tool.\n* Participation in structured outpatient physiotherapy (\\>1 times\u002Fweek), or day rehab programme.","21 Years",{"count":148,"type":20},220,[23],"This study investigates the effectiveness and implementation of an AI-assisted rehabilitation tool for adults with frailty in the real-world. The main questions it aims to answer are:\n\nDoes AI-assisted rehabilitation among frail adults improve patients' physical outcomes? Is there a particular subgroup of frail subjects that will benefit most from AI-assisted rehabilitation?\n\nResearchers will compare AI-assisted rehabilitation to standard practice (advice and QR link for rehabilitation videos to be done at home) to see if AI-assisted rehabilitation improves clinical outcomes compared to standard practice.\n\nParticipants will either:\n\nUndergo an AI-assisted rehab with the AI-sensor tool or a standard practice post-discharge from community hospitals for 12 weeks.\n\nUndergo interval assessments of outcomes. Keep a diary of outpatient rehabilitations (if applicable for the subjects).",[27],[153,154],"hybrid effectiveness-implementation study","pragmatic","NOT_YET_RECRUITING","2025-09-09",{"date":158,"type":36},"2025-09-16",{"date":160,"type":20},"2025-12-01",{"date":162,"type":20},"2027-04-30",{"name":164,"class":43},"SingHealth Community Hospitals",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":172,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":176,"conditions":177,"keywords":188,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":79},"100605647","association-of-pocd-with-circulating-biomarkers-in-patients-undergoing-tur-of-bladder-tumor-100605647","NCT07165236","Association of POCD With Circulating Biomarkers in Patients Undergoing TUR of Bladder Tumor","Association of Perioperative Cognitive Dysfunction With Circulating Biomarkers of Neurological Damage in Patients Underging Transurethral Resection of Bladder Tumor","Inclusion Criteria:\n\n* adult patients from 18-80 years,\n* elective operations of tumor bladder cancer (TUR),\n* patients can communicate,\n* patients who can sign the information consent and questionnaires\n\nExclusion Criteria:\n\n* patients under the age of 18,\n* patients above 80 years,\n* patients who are unable to communicate\n* patients who do not understand informed consent for the research,\n* patients who are unable to write\n* emergency surgery,\n* patients with proven hypersensitivity to some of the drugs used in the study\n* patients in a state of shock, septic, or hemorrhagic patients with neurodevelopmental disorders","18 Years","80 Years",{"count":175,"type":20},42,"Bladder tumor is one of the most widespread tumors in the world, with increasing prevalence at the global level. One of the procedures in patients with bladder tumors is transurethral resection of the bladder (TURM) most often performed endoscopically under general anesthesia. This patient population has certain characteristics in common. One of them is exposure to common risk factors for the formation of bladder tumors, such as aniline dyes and solvents. These substances are associated with the onset of neurodegeneration and oxidative stress. Smoking is another factor that affects the formation of bladder tumor. A significant part of patients with bladder tumor are an elderly population, which is repeatedly exposed to surgical procedures, with numerous comorbidities, with a high risk of postoperative complications and the development of perioperative cognitive deficits, which can further complicate the postoperative course and further treatment. In the group of patients with a bladder tumor who will undergo TURM, no evaluation of risk factors related to perioperative cognitive deficit was performed, nor was there an examination of the perioperative cognitive deficit itself. In them, the identification of factors for postoperative cognitive disorder is essential. The concept of clinical frailty is becoming more important and relevant when providing healthcare services to patients. The use of the clinical frailty scale as a tool in clinical practice provides information on the adequate direction of care for patients. Decrease in muscle strength can lead to limitations in the functioning of a certain individuals. In recent years muscle strength has come to be a very important component of health, regardless of a person's age and clinical condition.The hand grip test is a test used to measure the maximum isometric strength of the hand and forearm muscles. The MMSE test and MoCA are the most frequently used methods in the detection of cognitive impairment in clinical and research fields. In addition to laboratory indicators of organic function, circulating indicators of neuroinflammation, like S100B and neuron-specific enolase, will be correlated with the patient's cognitive status.So far, no research has been conducted on the dynamics of indicators of organic function, circulating indicators of neuroinflammation, perioperative cognitive changes and clinical fraility in patients undergoing bladder tumor operation.",[178,179,27,180,181,182,183,184,185,186,187],"Cognitive Decline","Urinary Bladder Cancer","Biomarker","General Anesthesia","Hand Grip Strength","Cognitive Testing","Comorbidities","Demographic Data","Socio-economic Status","Perioperative Complications",[189,190,191,192,193,194],"general anesthesia","postoperative cognitive complications","urinary bladder neoplasm","perioperative period","frail older adult","S100b","2025-09-02",{"date":197,"type":36},"2025-09-10",{"date":199,"type":36},"2024-11-28",{"date":201,"type":20},"2029-10-01",{"name":203,"class":43},"Osijek University Hospital",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":16,"minAge":211,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":214,"conditions":215,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":79},"100572148","pictorial-fit-frail-scale-in-adults-admitted-to-the-icu-in-a-tertiary-center--an-observational-prospective-study-100572148","NCT06729502","Pictorial Fit-Frail Scale in Adults Admitted to the ICU in a Tertiary Center- an Observational Prospective Study","Pictorial Fit-Frail Scale in Adults Admitted to the Intensive Care Unit in a Tertiary Center- an Observational Prospective Study","Inclusion Criteria:\n\n* Older adults (age ≥ 60 years) who were admitted to the ICU for more than 24 hours at the participating centers\n\nExclusion Criteria:\n\n* Prior recent admission to an ICU (within 30 days)\n* Admissions for brain death evaluation.\n* Planned admissions to the ICU (i.e for percutaneous tracheostomy, for specific treatment under sedation).","60 Years",{"count":213,"type":20},1350,"Understanding the frailty levels of critically ill patients using the PFFS at time of admission to ICU.\n\nExploring any associations between frailty, other prognostic factors, and patient outcomes.",[27],"2025-07-22",{"date":218,"type":36},"2025-07-23",{"date":220,"type":36},"2025-01-26",{"date":222,"type":20},"2027-03",{"name":224,"class":43},"Rabin Medical Center",{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":21,"phases":234,"briefSummary":235,"conditions":236,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":44},"100493872","the-save-project-sarcopenia-and-vertigo-in-aging-patients-with-colorectal-cancer-100493872","NCT05710809","The SaVe Project-Sarcopenia and Vertigo in Aging Patients With Colorectal Cancer","SaVe","Inclusion Criteria:\n\n* Meet the criteria of the oncological departments of receiving neoadjuvant, adjuvant or first line palliative chemotherapy for colorectal cancer\n* ≥65 years of age at the time of signing the informed consent form\n* Able to speak and read Danish, and to provide a signed informed consent form\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status score of ≤2\n\nExclusion Criteria:\n\n* Chemotherapy treatment within two years and sequelae of neuropathy, or symptoms of dizziness or vertigo, or balance disturbance\n* Severe physical disability that hinders physical exercise\n* Dementia, psychotic disorders, or other cognitive diseases or conditions that hinder participation in a clinical exercise-based trial\n* Inability to sign informed content\n* Patients who have had a consultation in the geriatric outpatient clinic within the past six months",{"count":233,"type":20},150,[23],"The goal of this clinical trial is to learn about the cause of dizziness and decline in walking ability in in older adults ≥65 years during chemotherapy treatment for colorectal cancer. Another goal is to investigate if a comprehensive geriatric assessment and three months' specialized physical group-based exercise three times\u002Fweek can counteract muscle weakness, vertigo, instability, impaired walking balance, and neuropathy",[237,238,239,240,241,242,243,26,244,245,246,247,27,248,28,249,250,251,252,253,254,255],"Colorectal Cancer","Oncologic Complications","Comprehensive Geriatric Assessment","Vestibular Rehabilitation","Geriatric Oncology","Sarcopenia","Vertigo","Rehabilitation","Exercise","Geriatric","Elderly","Older Adults","Chemotherapy-induced Peripheral Neuropathy","Resistance Training","Balance Training","Postural Stability","Pragmatic Trial","Personal Medicine","Individualised","2025-04-02",{"date":258,"type":36},"2025-04-06",{"date":260,"type":36},"2023-02-20",{"date":262,"type":20},"2027-09",{"name":264,"class":43},"Rigshospitalet, Denmark",{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":272,"enrollmentInfo":273,"targetDuration":4,"studyType":21,"phases":275,"briefSummary":276,"conditions":277,"keywords":279,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":79},"100558167","a-multifaceted-nutrition-intervention-for-frailty-in-the-community-elderly-100558167","NCT06547593","A Multifaceted Nutrition Intervention for Frailty in the Community Elderly","A Multifaceted Nutrition Intervention for Frailty in the Community Elderly: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Frailty assessed by the frail phenotype\n2. Aged between 65 and 85 years old\n\nExclusion Criteria:\n\n1. Multiple serious diseases such as stroke, cerebral infarction, tumors, and severe cardiovascular and cerebrovascular diseases\n2. Disability, dementia; severe visual and hearing impairments, and physical activity impairment\n3. Moderate to severe anxiety and depression\n4. Unable to complete this study as requested","85 Years",{"count":274,"type":20},315,[23],"With world's older population is rapidly increasing. China's population aging process is also accelerating. Studies have shown that persistent frailty can increase the incidence of negative events in the elderly. However, research on elderly frailty in China is still in its early stages, and existing research in China mainly focuses on the definition of frailty, evaluation tools for frailty, and cross-sectional surveys of small populations. There is currently limited research on interventions.\n\nThe MultIfaceted NUtrition inTErvention for Frailty (minute) trial is a randomized, controlled trial to explore the trajectory characteristics and influencing factors of frailty in the community, the impact of nutritional interventions on the developmental trajectory of frailty in the elderly in the community and the management model and appropriate technology for the sustainable intervention of frailty in the elderly based on the community.\n\nA total of 315 frail older adults will be recruited from Beijing. After the screening period, the compliant participants will be randomized to the control group, the nutrition intervention group with the nutrition intervention alone, or the combined nutrition intervention group with combining exercise and nutrition, on a 1:1:1 ratio, for 3 months. The primary outcome is the change in SPPB from the baseline to the end of the study. The change in SPPB as a primary outcome, and frailty status, demographic information, health status, nutrition assessment, comprehensive geriatric assessment status, quality of life, intrinsic capacity, and mental elasticity as secondary outcomes will be measured using validated questionnaires and clinical examinations.\n\nThis trial adheres to the Declaration of Helsinki and guidelines of Good Clinical Practice. Signed informed consent will be obtained from all participants. The trial has been approved by the Peking University Institutional Review Board (approval number: IRB00001052-23178). The results will be disseminated through academic conferences and publications in international peer-reviewed journals.",[27,247,278],"Nutrition Disorders in Old Age",[280,281,282,283],"multifaceted nutrition","frail","elderly","community","2024-08-07",{"date":286,"type":36},"2024-08-09",{"date":288,"type":20},"2024-07-30",{"date":290,"type":20},"2025-12-31",{"name":292,"class":43},"Zhaofeng Zhang"]